Introduction
Breast cancer is a disease caused by a complex combination of genetic and environmental factors. It is one of the most common types of cancer affecting women in the Western world. In 2004 in the United States, it is estimated that more than 200,000 new cases of breast cancer will be diagnosed and over 40,000 will die of this disease. Linkage analysis of families with a high risk of breast cancer has identified two major susceptibility genes: BRCA1 and BRCA2. 1, 2 In the context of large, multiple-case families, the BRCA1 and BRCA2 genes are numerically the most important, accounting for more than 80% of families with six or more cases of both early-onset breast cancer and ovarian cancer. 3 However, the probability of harboring a mutation is much lower in families with fewer cases of the disease, and population studies have demonstrated that these genes account for only a minority of the overall familial risk of breast cancer. In fact, as many as 60% of families with site-specific female breast cancer cannot be explained by mutations in BRCA1 and BRCA2. 4, 5 In addition, mutations in these genes are relatively rare in the general population. Together they account for less than 10% of all breast cancer cases 4, 6 (Fig 1) . Therefore, the challenge is how to identify individuals at risk for the remaining cases. Conceivably, if we could identify the major genetic factors that contribute to breast cancer risk, we would be able to not only provide comprehensive early identification of individuals at risk but also tailor prevention and treatment regimens to adequately address specific molecular changes in these cancers.
BRCA1 and BRCA2 were identified and isolated by linkage analysis and positional cloning, 1,2 a strategy that works well for highly penetrant genes. To date, few additional candidate breast cancer susceptibility loci have been identified in families not attributable to any of the known genes. Recently, Kainu et al 7 reported evidence for a novel breast cancer susceptibility locus on chromosome 13q21. However, posterior studies concluded that if a susceptibility gene does exist at this locus, it would account for only a small proportion of non-BRCA1/2 families with multiple cases of early-onset breast cancer. 8 These findings illustrate the difficulties inherent in efforts to identify additional susceptibility genes for a highly prevalent disease and suggest that the traditional linkage approach may have reached its limit. Indeed, if current models are correct, the remaining predisposition genes are likely to have lower penetrance or be part of a polygenic effect and therefore difficult to isolate by linkage. 9 Some of the candidate low-penetrance genes have been proposed to be proto-oncogenes, genes involved in metabolic, estrogen, and immunomodulatory pathways. 10, 11 In particular, genes in hormonal metabolism pathways have received increased attention, but research on the impact of these genes on breast cancer risk is still at an early stage.
In the 10 years since the cloning of the first breast cancer susceptibility gene, BRCA1, our knowledge of Germline mutations in the two major susceptibility genes BRCA1 and BRCA2 account for less than 5% of all breast cancer cases, while mutations in genes such as ATM, CHEK2, PTEN, and TP53 account for only about 1% of all breast cancer cases. The genetic factors underlying sporadic breast cancer cases are largely unknown.
breast cancer has significantly improved. 1, 12 It is possible that understanding the function of the genes identified so far may allow us to make better informed choices of candidate genes to be studied. Besides BRCA1 and BRCA2, several other genes whose inactivation predisposes to breast cancer have been identified such as ATM, TP53, CHEK2, and PTEN. Although many of these genes are associated with rare hereditary diseases such as Li-Fraumeni syndrome (TP53 and CHEK2), Cowden disease (PTEN), and ataxia telangiectasia (ATM) and therefore are unlikely to be major contributors to risk in the general population, they highlight a common characteristic: several play a role in the cellular response to DNA damage (Fig 2) . In a simplistic view, one could consider the DNA damage response as composed of processes sensing and signaling the presence of damage and processes involved in the actual repair of the DNA strands. In this view, the known breast cancer predisposition genes seem to be involved in sensing and signaling damage rather than being directly involved in DNA repair.
Damage of genomic DNA occurs spontaneously and constantly throughout the life of an organism and can be further enhanced by exogenous DNA damaging factors. Therefore, an efficient response to DNA damage is essential for cellular life. Spontaneous DNA damage results from errors in fundamental cellular processes such as DNA replication. Exogenous DNA damage factors include environmental pollution, ionizing radiation, ultraviolet rays, and chemotherapeutic drugs. The most detrimental form of DNA damage is chromosomal double-strand break (DSB), which is lethal to the cell if not repaired. DNA DSB can be induced by ionizing radiation, DNA replication errors, or cell oxidative metabolism. Two major pathways for the repair of DSBs in mammalian cells include homologous recombination (HR) repair, which essentially provides an error-free repair by using a homologous template (the homologous chromosome or the sister chromatid) and the more error-prone nonhomologous end joining. 13, 14 Regardless of which mechanism is used, mistakes may introduce mutations that in some cases will promote tumorigenesis. Both pathways consist of a complex network of events that trigger cell cycle checkpoints to prevent cells from progressing through the cycle with damaged DNA and activate a specific DNA repair mechanism (Fig 2) . A number of genes involved in the DNA DSB repair pathway have been implicated as breast cancer susceptibility genes. Below we review what is known about the function of these genes in an attempt to understand how it impinges on breast cancer risk and to propose other genes that may be involved in predisposition.
BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185)
One defective copy of BRCA1 or BRCA2 in the germline is sufficient for breast cancer predisposition, but the loss of the second allele is required for cancer development. However, little is known about the mechanisms by which the wild-type allele is lost. Surprisingly, despite the association with inherited predisposition, somatic mutations in BRCA1 and BRCA2 are rare in sporadic breast cancer. 15, 16 BRCA1 and BRCA2 encode large nuclear proteins, widely expressed in different tissues, markedly during S and G 2 phases. They bear little resemblance to one another or to other proteins of known function. 17 Orthologs are not found in the yeast or fly, but a BRCA1 ortholog in the worm Caenorhabditis elegans has been recently reported, suggesting a peculiar track in evolution. 18 Both BRCA1 and BRCA2 have been consistently linked to various processes involved in the DNA damage response. These include the repair of DSBs by HR, the repair of oxidative damage by transcription-coupled repair, and a possible role in nonhomologous end joining. [19] [20] [21] BRCA1 and BRCA2 are also implicated in the maintenance of chromosome stability, possibly through their function in recombination. 12, 17, 22 Mouse and human cells null for BRCA1 and BRCA2 suffer from chromosome instability and have a heightened sensitivity to DNA lesions that are normally repaired by HR. 23, 24 Models have also been proposed to explain the roles of BRCA1 and BRCA2 in maintenance of chromosome instability through functions in DNA replication. 25 Stalled replication forks caused by a variety of mechanisms (eg, base lesions, DNA breaks, or strand gaps) are thought to require HR to restart replication. If HR is dysfunctional, then stalled replications forks may lead to persistent DNA breaks and ultimately to gross chromosomal rearrangements, including translocations. These are frequently seen in cells lacking BRCA1 Fig 2. -Breast cancer susceptibility gene products and the DNA damage response pathway. In this simplified view, ATM is activated by the presence of DNA double-strand breaks (DSB) and phosphorylates CHEK2, BRCA1, and TP53. Activated CHEK2 also phosphorylates TP53 and BRCA1. Phosphorylation of these proteins seems to be required for the efficient activation of various cell cycle checkpoints. BRCA2 regulates the function of the RAD51 protein, which bridges the interaction between BRCA1 and BRCA2. Another protein implicated in breast cancer predisposition, PTEN, mediates down-regulation of AKT. Pointed arrowheads indicate activation, and flat arrowheads indicate inhibition. and BRCA2. 24 Such rearrangements may well provide the raw material for the further genetic changes required for tumor progression. 26 Alternatively, chromosomal instability initiated by BRCA deficiency may be the result of incorrect routing of DSB processing down an inappropriate pathway rather than the failure of repair per se. 17 In this model, DSBs in BRCA-deficient cells are rerouted for repair by mechanisms that are potentially error-prone (nonhomologous end joining or single strand annealing) because the preferred mode of (error-free) processing by HR is unavailable.
The exact molecular functions of BRCA1 in the DNA damage response have remained elusive. Although arbitrary and complicated, the classification of the proteins involved in the DNA damage response as sensors, transducers, or effectors is helpful for a systematic analysis. 27 In this view, BRCA1 is likely to participate as a sensor or transducer rather than directly as a repair factor (effector). 27 Some hints can be gleaned from the protein-protein interaction partners of BRCA1. BRCA1 interacts with Rad51 and the MR11/RAD50/Nbs1 protein complex, which participates in DSB repair. [28] [29] [30] BRCA1 may also have local activities at DSB sites through its interaction with enzymes that alter chromatin and DNA structure. BRCA1 interacts with SWI/SNF and other proteins that remodel chromatin, such as regulators of acetylation/ deacetylation, and with DNA helicases, including the RecQ homolog encoded by the Bloom's syndrome gene, BLM, and the novel helicase BACH1. [31] [32] [33] [34] [35] These data suggest a role for BRCA1 as a scaffold or platform to coordinate different activities needed for repair. The molecular role of BRCA2 is somewhat better understood. BRCA2 interacts with and regulates the function of RAD51, the mammalian homolog of Escherichia coli RecA that has a catalytic activity central to HR.
36 RAD51 coats single-strand DNA to form a nucleoprotein filament that invades and pairs with a homologous DNA duplex, initiating strand exchange between the paired DNA molecules. The interaction involves a substantial proportion of total cellular pool of each protein, suggesting that BRCA2 works directly to regulate the availability and activity of RAD51 in this key reaction. 37 Taken together, these observations place BRCA1 and BRCA2 firmly in the DNA damage response pathway and suggest a pleiotropic role in this pathway.
ATM (OMIM 607585)
The ATM (ataxia telangiectasia-mutated) protein was identified as the product of the gene mutated in the rare human autosomal recessive disorder ataxia telangiectasia (AT). 38 ATM is a serine/threonine protein kinase that belongs to the phosphatidyl inositol 3-kinase super family. The ATM kinase plays a central role in response to DSB, and loss of ATM abolishes the checkpoints at the G 1 -S transition, in S phase, and at the G 2 -M boundary. 27 AT is characterized by neurodegeneration, immunodeficiency, genomic instability, hypersensitivity to ionizing radiation, and increased cancer predisposition. 39 It is estimated that approximately 1% to 2% of the general population may be heterozygote carriers of the ATM gene but do not show any of the major disease symptoms. However, certain types of ATM mutations in heterozygous carriers seem to increase cancer predisposition, particularly breast cancer. [40] [41] [42] The majority of mutations identified in the gene are truncating mutations resulting in unstable truncated protein products, leaving heterozygous carriers of such mutations with a reduced level of functional ATM protein produced by a wild-type allele. 43 However, ATM truncations do not contribute to early-onset breast cancer. 44 The early studies of the relationship between ATM heterozygosity and breast cancer risk were inconclusive, and neither linkage analyses nor mutation studies provided supporting evidence for a role of ATM in breast cancer predisposition. An explanation that clarified these initial findings came from a missense mutation model. 45 The model defines two groups of ATM heterozygous mutations in the general population that cause different degrees of cancer predisposition. One group has a truncated allele and a second group has a missense mutation. These missense mutations allow production of full size, stable, but functionally inactive ATM protein, and they act as dominant negative mutations interfering with the function of the normal allele. Carriers of these mutations have a high predisposition for breast cancer. This explanation is further supported by linkage and penetrance analysis of ATM mutations among breast cancer cases. 46 Additional support for this model came from a study of ATM "knock-in" heterozygous mice harboring an in-frame deletion corresponding to the human 7636del9 mutation. 47 The ATM "knock-in" showed an increased susceptibility to developing tumors. In contrast, no tumors were observed in the ATM heterozygous (Atm +/-) mice.
A mechanistic understanding of the different roles for truncating and missense mutations in breast cancer predisposition came from the elegant work of Bakkenist et al. 48 They found that ATM molecules exist as dimers or higherorder multimers in undamaged cells where the kinase domain of each monomer is bound to an internal domain of another neighboring ATM molecule containing the catalytic site. While in this state,ATM is inactive and unable to phosphorylate its substrates. After DNA damage, the kinase domain of one ATM molecule phosphorylates another ATM molecule in the dimer complex, and the phosphorylated ATM dissociates from the complex to phosphorylate other substrates. Thus, kinase inactive and nonphosphorylatable missense mutants of ATM are locked in the inactive complex. This mechanism of activation provides an explanation for the dominant-negative effect of ATM heterozygous missense mutations. However despite the prevalence of the AT mutations in the population, the risk conferred by AT heterozygosity is still too low to account for a large pro-portion of familial breast cancers. The degree to which the ATM gene contributes to sporadic breast cancer will require further studies and mutation screening. Nevertheless, its central role in the DNA damage response reinforces the notion that this pathway may be intrinsically linked to breast cancer predisposition.
TP53 (OMIM 191170)
Breast cancer is a major component of the rare Li-Fraumeni syndrome, in which germline mutations of the TP53 gene have been documented. 49, 50 Li-Fraumeni syndrome is an autosomal-dominant disease characterized by early occurrence of multiple cancers such as sarcomas, breast cancer, brain tumors, leukemia, and adrenal cortical tumors. 50 It is estimated that 50% of women who survive childhood cancers will develop breast cancer by the age of 50, and lifetime penetrance approaches 100%. 51 Although highly penetrant, the Li-Fraumeni genes account for less then 1% of breast cancer cases.
51
TP53 is a tumor suppressor gene encoding a nuclear phosphoprotein that acts as a transcription factor involved in the control of cell cycle progression, repair of DNA damage, genomic stability, and apoptosis. 52 In response to DNA damage, the p53 protein arrests cells in the G 1 phase of the cell cycle, allowing the DNA repair mechanism to proceed prior to DNA synthesis. Loss of p53 function abolishes this growth arrest response to DNA damage. Interestingly, TP53 mutations are frequently found in BRCA1-linked tumors and several studies have suggested that the status of BRCA1/BRCA2 influences the type and distribution of TP53 mutations in breast cancer. [53] [54] [55] In conclusion, mutations in p53 are a rare cause of breast cancer except for those associated with Li-Fraumeni syndrome. While TP53 is one of the most commonly mutated genes in human tumors, among sporadic breast tumors only a small fraction carries a TP53 mutation. 56 Importantly, p53 is a key regulator of the response to DNA damage and, similar to BRCA1, a substrate for damageinduced ATM phosphorylation.
CHEK2 (OMIM 604373)
Germline mutations in the CHEK2 (CHK2) gene have also been implicated in the etiology of Li-Fraumeni syndrome. 57 This gene encodes the human ortholog of yeast checkpoint kinases Cds1 and Rad53 in Schizosaccharomyces pombe and Saccharomyces cerevisiae, respectively. 58 In mammalian cells, CHEK2 is phosphorylated by ATM in response to DSB. 59 Activated CHEK2 phosphorylates a number of target proteins that in turn prevent cellular entry into mitosis and activate DNA repair pathways. In addition, CHEK2 acts in the G 1 -S checkpoint by phosphorylating p53 and mediating activation and stabilization of p53 by ATM. 60, 61 In another important connection, CHEK2 phosphorylates Cdc25C and BRCA1. 58, 62 Mutation screening of the CHEK2 gene among Li-Fraumeni cases revealed a deletion mutation CHEK2 1100delC, which inactivates the kinase activity of the protein. 57 This allele has also been proposed to be a low-penetrance breast cancer susceptibility allele.
63,64
Additional screening of CHEK2 variants did not identify any other variant that occurs at significantly elevated frequency, indicating that 1100delC may be the only CHEK2 allele with a significant contribution to breast cancer susceptibility. 65 Interestingly, CHEK2 1100delC is associated with breast cancer only in noncarriers of BRCA1 and BRCA2. 63 A recent search for new breast cancer susceptibility genes among families with no BRCA1 and BRCA2 mutation suggested a model in which CHEK2 1100delC interacts with an as yet unknown gene to increase breast cancer risk. 66 Although the CHEK2 1100delC allele confers moderate risk, its prevalence suggests that it may be a more important player in breast cancer incidence than genes associated with breast cancer only in the context of rare hereditary syndromes. Again, the cross talk between CHEK2 and the other breast cancer predisposition gene products in the DNA damage pathway is evident.
PTEN/MMAC1 (OMIM 601728)
PTEN (also known as MMAC1) was originally identified as a tumor suppressor gene defective in a variety of human cancers. 67, 68 Germline mutations in PTEN are associated with Cowden disease, a rare autosomal dominant inherited cancer syndrome characterized by a high risk of breast, thyroid, and endometrial carcinomas. [69] [70] [71] Most cancerassociated PTEN mutations are truncations that cause a 25% to 50% lifetime breast cancer risk among women affected with Cowden disease.
72,73 PTEN mutations are rare in sporadic breast cancer and have been found in only 5% of the sporadic cases. 74, 75 However, 29% to 48% of sporadic breast cancer cases show loss of heterozygosity at the PTEN locus, while no alterations have been found in the remaining allele. 76 In addition, approximately 40% of breast cancers show a decrease or absence of PTEN protein levels.
PTEN is a phosphatase with dual specificity for proteins and major cellular lipids. Its tumor suppressor function has been linked to its lipid phosphatase activity, which is specific for the position 3 of major cellular lipids phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 3,4,-bisphosphate, both byproducts of the lipid kinase activity of the phosphoinositide 3-kinase (PI3K). 77 The PI3K pathway regulates cell growth and survival through signaling to its downstream effectors, the protein kinases AKT and PDK1. Among numerous AKT kinase substrates are members of the FOXO forkhead transcription factors subfamily. 78 Activated AKT kinase pro-motes phosphorylation and subsequent inactivation of the FOXO family members. Interestingly, in PTEN-deficient cells the FOXO transcription factors are aberrantly localized to the cytoplasm and cannot activate transcription. 79 In addition, PTEN-mediated down-regulation of AKT stimulates transcription of the cyclin-dependent kinase inhibitors p27 Kip1 , p21 Waf1/Cip1 , and p57 Kip2 . 79 Importantly, the FOXO transcription factors modulate expression of several genes that regulate cellular response to DNA damage linking PTEN/PI3K/AKT pathway to DNA damage repair pathway. 80 
Searching for Additional Genes
It is clear that mutations in BRCA1 and BRCA2 genes not only cause defects in DNA repair after DSB but also predispose carriers to breast cancer. In addition, other known breast cancer susceptibility genes such as ATM, CHEK2, and TP53 also function in the DNA damage response pathway. Inactivation of PTEN, although less clear than the above-mentioned genes, also seems to impinge on the ability of cells to respond to damage. While it is possible that the apparent clustering of predisposition genes in this pathway may be restricted to the rare hereditary syndromes described above, it is plausible to think that they reveal important common characteristics in the biology of breast cancer susceptibility. The reason why this ubiquitous pathway is specifically tied to breast cancer predisposition remains unknown. Although there is no clear explanation for that, recently several hypotheses, at least in the context of BRCA1 inactivation, have been formalized and can now be experimentally tested.
12, 25, 81, 82 If the DNA damage response pathway were a major target of inactivation in breast cancer, we would predict that other known genes would be targets of germline or somatic mutations. In fact, screens to identify mutations in DNA damage response genes as well as association studies using candidate polymorphisms have been undertaken (Table) ing, signaling, and amplifying the damage signal. 27 Therefore, a candidate gene approach focusing on genes whose products are involved in signaling DNA damage (eg, CHK1, Claspin, 53BP1, and ATRIP) may prove more fruitful when combined with a better understanding of the biochemistry of the DNA damage response. Another possible reason for the relative failure of the candidate gene approach may be due to the fact that inactivating mutathese studies provide enough evidence to keep the issue alive. The reasons for the inability to identify any major additional gene are unknown. Interestingly, although we still have an incomplete understanding of the biochemistry involved in DNA damage response and repair, it could be argued that many of the studies have focused on proteins involved in the DNA repair process, while the known predisposition genes seem to be involved in sens- tions in these genes have, in isolation, only small effects on risk. The implication is that significant increases in risk will be apparent only when combined with mutations in additional genes. This scenario would be analogous to synthetic lethality in yeast, where two mutations in separate genes are viable as single mutations but lethal when combined. Several of the association studies mentioned here and presented in the Table suggest that this is the case. For example, while mutations in certain genes had marginal or no association with risk when studied in isolation, they showed significant association when combined with variant alleles in other genes. 91, 109 Novel methods to identify synthetic gene interactions in multicellular organisms have only now become possible by exploiting RNA interference. 120 It is also important not to be limited to the usual suspects. Genome-wide association studies using single nucleotide polymorphisms (SNPs) are unbiased in that there is no preconceived idea about which genes are likely to be involved in the disease process and will be instrumental in identifying other candidate pathways. 121, 122 However, large data sets and appropriate SNP genome coverage are needed, putting this approach beyond the reach of smaller laboratories. It is expected that as technology improves and costs decrease, this approach will have widespread use.
In the near future, we can look forward to the identification of novel breast cancer predisposing genes due to rapid advancement of gene discovery technologies. The identification and functional characterization of such genes will have a significant impact on breast cancer research and early detection. A major challenge for researchers will be to understand the complicated mechanisms and changes that lead to the development and progression of breast cancer and to apply that knowledge to breast cancer detection, prevention, and treatment. suggesting that it is associated with BC. MS = mutation screening, AS = association study, BC = breast cancer, B/OC = breast/ovarian cancer, LOH = loss of heterozygosity. a Missense changes are shown in three-letter code for amino acids. Noncoding changes are indicated by the nucleotide change. b The results displayed here are a summary of the overall results and are only confined to the findings as pertaining to breast cancer. Results differ for the association of a certain single nucleotide polymorphism with other cancers, or for combinations with other genetic and environmental factors but that is not listed here. Readers are encouraged to consult the original papers for a full analysis and discussion as well as a review by Goode et al 119 discussing polymorphisms in DNA repair genes and cancer in general. (continued from page 133) 
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